1. Biomarkers in Liquid Biopsies for Prediction of Early Liver Metastases in Pancreatic Cancer.
- Author
-
Mehdorn, Anne-Sophie, Gemoll, Timo, Busch, Hauke, Kern, Katharina, Beckinger, Silje, Daunke, Tina, Kahlert, Christoph, Uzunoglu, Faik G., Hendricks, Alexander, Buertin, Florian, Wittel, Uwe A., Sunami, Yoshiaki, Röcken, Christoph, Becker, Thomas, and Sebens, Susanne
- Subjects
- *
PANCREATIC tumors , *LIVER , *INFLAMMATION , *METASTASIS , *CELL physiology , *CELL motility , *TUMOR markers , *TUMOR antigens , *EARLY diagnosis ,BODY fluid examination - Abstract
Simple Summary: Individualized diagnostics approaches in modern cancer therapy require predictive and prognostic biomarkers that are easily accessible and stratify patients for optimal and individualized treatment. Pancreatic ductal adenocarcinoma (PDAC) is still a life-threatening disease mainly because of its late diagnosis in advanced stages or rapid progress even in patients with curative resection of the primary tumor. Moreover, patients with liver metastases exhibit an even worse prognosis. Hence, this retrospective multi-center study aims to identify biomarkers in perioperative serum of PDAC patients predicting early liver metastasis. A highly sensitive biomarker analysis was performed using two different methodological approaches. Olink® analysis, which was also used to validate LEGENDplexTM results, identified significant differences in proteins involved in chemotaxis and migration of immune cells as well as cell growth in serum of patients with early versus late onset of liver metastasis. Further studies with larger cohorts are required to validate these findings for clinical translation. Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive solid malignancies with poor survival rates. Only 20% of the patients are eligible for R0-surgical resection, presenting with early relapses, mainly in the liver. PDAC patients with hepatic metastases have a worse outcome compared to patients with metastases at other sites. Early detection of hepatic spread bears the potential to improve patient outcomes. Thus, this study sought for serum-based perioperative biomarkers allowing discrimination of early (EHMS ≤ 12 months) and late hepatic metastatic spread (LHMS > 12 months). Serum samples from 83 resectable PDAC patients were divided into EHMS and LHMS and analyzed for levels of inflammatory mediators by LEGENDplexTM, which was validated and extended by Olink® analysis. CA19-9 serum levels served as control. Results were correlated with clinicopathological data. While serum CA19-9 levels were comparable, Olink® analysis confirmed distinct differences between both groups. It revealed significantly elevated levels of factors involved in chemotaxis and migration of immune cells, immune activity, and cell growth in serum of LHMS-patients. Overall, Olink® analysis identified a comprehensive biomarker panel in serum of PDAC patients that could provide the basis for predicting LHMS. However, further studies with larger cohorts are required for its clinical translation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF